Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Quanterix Corporation - Common Stock (NQ:QTRX)

3.350 +0.050 (+1.52%)
Streaming Delayed Price Updated: 9:45 AM EDT, May 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 65,202
Open 3.390
Bid (Size) 3.340 (200)
Ask (Size) 3.350 (600)
Prev. Close 3.300
Today's Range 3.340 - 3.450
52wk Range 2.950 - 8.770
Shares Outstanding 38,063,618
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer’s Biomarker Testing into Clinical Workflows
From Quanterix
Via Business Wire
News headline image
Quanterix To Report First Quarter 2026 Financial Results on May 6, 2026
From Quanterix Corporation
Via Business Wire

Performance

YTD
-47.9%
-47.9%
1 Month
-11.6%
-11.6%
3 Month
-48.5%
-48.5%
6 Month
-36.7%
-36.7%
1 Year
-44.3%
-44.3%

More News

Read More
News headline image
AidaBREAST™ Multi-Omic Assay Demonstrates Spatial Proteomics for Clinical Oncology
From Quanterix Corporation
Via Business Wire
News headline image
Quanterix Corporation Announces Date of 2026 Annual Meeting
From Quanterix Corporation
Via Business Wire
Quanterix Corp (NASDAQ:QTRX) Tops Q4 Revenue Estimates, Provides 2026 Guidance ↗
Via Chartmill
News headline image
Earnings Scheduled For November 10, 2025 ↗
Via Benzinga
News headline image
Earnings Preview For Quanterix ↗
Via Benzinga
News headline image
Quanterix (QTRX) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Quanterix Releases Financial Results for the Fourth Quarter and Full Year 2025
From Quanterix Corporation
Via Business Wire
News headline image
Lucent Diagnostics and Life Line Screening Partner to Bring Advanced Blood-Based Diagnostics to Communities Nationwide
From Quanterix
Via Business Wire
News headline image
Quanterix to Participate in Upcoming Investor Conferences
From Quanterix Corporation
Via Business Wire
News headline image
Quanterix To Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026
From Quanterix
Via Business Wire
News headline image
Quanterix Announces FDA 510(k) Submission for a Multi-Analyte Algorithmic Blood Test for Alzheimer’s Disease Detection
From Quanterix Corporation
Via Business Wire
News headline image
Quanterix Announces Landmark JAMA Study Highlighting Prognostic Value of Multi-Analyte Approach to Blood-Based Alzheimer’s Risk Profiling
From Quanterix Corporation
Via Business Wire
News headline image
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Quanterix Corporation
Via Business Wire
What's going on in today's session ↗
Via Chartmill
Keep an eye on the top gainers and losers in Friday's session. ↗
Via Chartmill
News headline image
Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026
From Quanterix Corporation
Via Business Wire
News headline image
Quanterix Announces Landmark Nature Study Redefining Alzheimer’s Disease Neuropathology Prevalence
From Quanterix Corporation
Via Business Wire
News headline image
Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth
From Quanterix Corporation
Via Business Wire
News headline image
Quanterix Announces Landmark Study Demonstrating Dual GFAP/NfL Blood Test Approach for Personalized Multiple Sclerosis Monitoring
From Quanterix Corporation
Via Business Wire
News headline image
Quanterix Releases Financial Results for the Third Quarter of 2025
From Quanterix Corporation
Via Business Wire
News headline image
Quanterix To Report Third Quarter 2025 Financial Results on November 10, 2025
From Quanterix
Via Business Wire
News headline image
The Silent Architects: How Institutional Investors Shape Stock Performance and Market Destiny
Via MarketMinute
Topics Artificial Intelligence Bankruptcy Economy
News headline image
Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit
From Quanterix Corporation
Via Business Wire

Frequently Asked Questions

Is Quanterix Corporation - Common Stock publicly traded?
Yes, Quanterix Corporation - Common Stock is publicly traded.
What exchange does Quanterix Corporation - Common Stock trade on?
Quanterix Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Quanterix Corporation - Common Stock?
The ticker symbol for Quanterix Corporation - Common Stock is QTRX on the Nasdaq Stock Market
What is the current price of Quanterix Corporation - Common Stock?
The current price of Quanterix Corporation - Common Stock is 3.350
When was Quanterix Corporation - Common Stock last traded?
The last trade of Quanterix Corporation - Common Stock was at 05/06/26 09:45 AM ET
What is the market capitalization of Quanterix Corporation - Common Stock?
The market capitalization of Quanterix Corporation - Common Stock is 127.51M
How many shares of Quanterix Corporation - Common Stock are outstanding?
Quanterix Corporation - Common Stock has 128M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.